TA
IRWD icon

Tamarack Advisers’s Ironwood Pharmaceuticals IRWD Stock Holding History

Tamarack Advisers’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-225,000
Closed -$2.39M – 29
2023
Q2 		$2.39M Buy
225,000
+15,000
+7% +$161K 0.74% 23
2023
Q1 		$2.21M Buy
210,000
+35,000
+20% +$392K 0.81% 22
2022
Q4 		$2.17M Buy
+175,000
New +$1.99M 1.12% 27

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Tamarack Advisers's IRWD Position: Q3 2023 in Review

Tamarack Advisers sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2023, closing a stake of 225,000 shares — an estimated $2.39M sold.

Tamarack Advisers first reported a position in IRWD in Q4 2022 and held it in 3 quarters. The position peaked at $2.39M in Q2 2023. 248 funds tracked by Wall St. Rank hold IRWD as of Q3 2023.

  • Tamarack Advisers reported no remaining Ironwood Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Tamarack Advisers sold 225,000 Ironwood Pharmaceuticals shares in Q3 2023, an estimated $2.39M.
  • Tamarack Advisers first reported a position in Ironwood Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Tamarack Advisers's Ironwood Pharmaceuticals position peaked at $2.39M in Q2 2023.
  • 248 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2023.

Based on Tamarack Advisers's 13F filing for Q3 2023, filed 16 Nov 2023.